HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI

Author:

Mok Tony1ORCID,Jänne Pasi A2ORCID,Nishio Makoto3ORCID,Novello Silvia4ORCID,Reck Martin5ORCID,Steuer Conor6ORCID,Wu Yi-Long7ORCID,Fougeray Ronan8ORCID,Fan Pang-Dian8ORCID,Meng Jie8ORCID,Sternberg David W8ORCID,Esker Stephen8,Yu Helena A9ORCID

Affiliation:

1. Department of Clinical Oncology, State Key Laboratory of Translational Oncology & Chinese University of Hong Kong, Hong Kong, Hong Kong PRC

2. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

3. Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

4. Oncology Department at San Luigi Hospital in Orbassano, University of Turin, 10124 Torino, Italy

5. Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic, 22927 Grosshansdorf, Germany

6. Hematology & Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA

7. Lung Cancer Institute, Guangdong Province People's Hospital, Guangzhou, China, 510317

8. Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ 07920, USA

9. Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Abstract

After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses. Therapies with greater efficacy and tolerable safety profiles are needed in this setting. The receptor tyrosine kinase HER3 is widely expressed in NSCLC, and increased expression is associated with poor treatment outcomes. In the U31402-A-U102 phase I trial, HER3-DXd showed promising antitumor activity with manageable safety in heavily pre-treated patients with EGFR-mutated NSCLC across a range of tumor HER3 expression levels and EGFR TKI resistance mechanisms. HERTHENA-Lung02 is the first phase III trial to evaluate the safety and efficacy of HER3-DXd versus PBC in patients with progression on a third-generation EGFR TKI. Clinical Trial Registration: NCT05338970  ( clinicaltrials.gov ); 2021-005879-40 (EudraCT Number).

Funder

Daiichi-Sankyo

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3